Insight Molecular Diagnostics

IMDX

Market cap $204M

NASHVILLE, Tenn., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today congratulated the STAR working group on its position paper in the American Journal of Transplantation in recognizing the need for decentralized organ health testing in the global transplant community.

NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following investor conferences this winter, which will include hosting meetings around the annual J.P.

NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), or iMDx, today announced that it has appointed Dr. Nick Ioannou, M.D., MHA, to the position of Vice President, Medical Affairs.

NASHVILLE, Tenn., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today provided a year-end business update regarding its commercial progress, its GraftAssureDx™ test kit clinical trial and planned in vitro diagnostic (IVD) de novo submission to the United States Food & Drug Administration (FDA), as well as its plans for additional regulatory submissions and registry study progress in 2026.

Insight Molecular Diagnostics Inc. ( IMDX ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Gabrielle Woody - Sr. Executive Assistant Joshua Riggs - President, CEO & Director Andrea James - Chief Financial Officer Ekkehard Schutz - Chief Science Officer Conference Call Participants Mark Massaro - BTIG, LLC, Research Division Harrison Parsons - Stephens Inc., Research Division Michael Matson - Needham & Company, LLC, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Presentation Gabrielle Woody Sr. Executive Assistant Greetings, everyone, and welcome, everyone, and thank you for joining us to discuss Insight Molecular Diagnostics Third Quarter 2025 Results. If you have not seen today's shareholder letter, please visit Insight Molecular Diagnostics Investor Relations page at investors.imdxinc.com.

On track to submit GraftAssureDx™ for FDA review by year-end On track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025 GraftAssure assay's head-to-head data continue to be favorable Preparing to rapidly expand beyond kidney into heart transplant testing NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its third quarter results:  Fellow shareholders, There is a palpable level of excitement and activation energy coursing through our company as we prepare to submit our application for approval of our first molecular diagnostic test kit for clinical use, GraftAssureDx™, to the FDA.

NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 10, 2025.

NASHVILLE, Tenn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it has welcomed Steven Tahmooressi to its executive leadership team as the company prepares to launch its first clinical kitted assay in 2026.

NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced results from a study conducted by iMDx researchers and partners published in the American Journal of Transplantation, that demonstrated the value of its GraftAssure assay for long-term monitoring of a kidney transplant patient with severe complications requiring novel therapy.

NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced attendance at two key industry conferences where it will discuss its GraftAssure™ technology, including its clinical kitted test under development.